aspirin has been researched along with everolimus in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 25 (73.53) | 24.3611 |
| 2020's | 7 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Acampado, E; Farb, A; John, M; Kolodgie, FD; Prescott, MF; Virmani, R | 1 |
| Akishita, M; Ako, J; Eto, M; Iijima, K; Ogawa, S; Ota, H; Ouchi, Y | 1 |
| Caixeta, A; Gordon, P; Hermiller, JB; Jonnavithula, L; Lansky, AJ; Miquel-Hebert, K; Onuma, Y; Ruygrok, P; Serruys, PW; Sood, P; Stone, GW; Su, X; Sudhir, K; Veldhof, S; Yaqub, M | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Devlin, G; Hyde, L; Liang, M; Liew, TV; Puri, A | 1 |
| Ferraro, G; Gaita, F; Marcolongo, M; Moretti, C; Sheiban, I; Truffa, A | 1 |
| Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S | 1 |
| den Heijer, P; Goy, JJ; Hofma, S; Nouche, RT; Serra, A; Slagboom, T; Smits, PC; Togni, M; Valdés, M; van der Ent, M; Vázquez, N; Voudris, V; Vuillomenet, A | 1 |
| McClean, D; Puri, A; Saireddy, R | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Huang, KN | 1 |
| Alfonso Manterola, F; Doncel Vecino, LJ; Fernández Díaz, JA; Fernández Portales, J; González Fernández, R; López Mínguez, JR; Martínez Cáceres, G; Martínez Romero, P; Merchán Herrera, A; Nogales Asensio, JM; Romany, S; Sandoval, J | 1 |
| Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D | 1 |
| Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW | 1 |
| Jim, MH; Wong, KL; Yiu, KH | 1 |
| Guo, XF; Han, YL; Li, B; Liu, Q; Lu, SZ; Pang, S; Su, X; Xu, B; Yang, YJ; Zhang, YJ; Zhao, YL | 1 |
| Akasaka, T; Hanawa, K; Hao, K; Hasebe, Y; Hirano, M; Ito, K; Matsumoto, Y; Miyata, S; Nishimiya, K; Ogata, T; Oyama, K; Shimokawa, H; Shindo, T; Takahashi, J; Tanaka, A; Taruya, A; Tsuburaya, R; Uzuka, H | 1 |
| Caixeta, A; Généreux, P; Hermiller, JB; Jones-McMeans, J; Kedhi, E; Krucoff, MW; Palmerini, T; Rutledge, DR; Serruys, PW; Simonton, CA; Stone, GW; Sudhir, K; Wang, J | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ito, M; Izumi, D; Miyahara, M; Sakai, M | 1 |
| Chang, K; Choi, YS; Chung, WB; Chung, WS; Kim, HY; Kim, JY; Kwon, A; Lee, MY; Park, CS; Seung, KB | 1 |
| Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW | 1 |
| Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Fujii, T; Hayashi, T; Hirata, KI; Igarashi, N; Ishihara, T; Kadotani, M; Kawamori, H; Matsumoto, D; Matsuura, A; Nagano, Y; Nagasawa, A; Okada, M; Onishi, H; Otake, H; Sakakibara, T; Shinke, T; Shite, J; Sugizaki, Y; Takeshige, R; Toba, T; Tsukiyama, Y; Yamamoto, H; Yanaka, K; Yasaka, Y | 1 |
| Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T | 1 |
| Abe, M; Ando, K; Igarashi Hanaoka, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakao, K; Natsuaki, M; Tanabe, K; Watanabe, H | 1 |
| Yokoyama, H | 1 |
| Angiolillo, DJ; Bangalore, S; Bhatt, DL; Cao, D; Chehab, BM; Ge, J; Hermiller, J; Makkar, RR; Maksoud, A; Mehran, R; Neumann, FJ; Picon, H; Saito, S; Toelg, R; Valgimigli, M; Wang, J; Wang, LJ | 1 |
| Haruta, H; Hirayama, A; Hiro, T; Kitano, D; Kurosawa, T; Li, Y; Matsumoto, T; Migita, S; Mitsumata, M; Okumura, Y; Sudo, M; Takahashi, R; Takayama, T; Taniguchi, Y | 1 |
| Babayiğit, E; Çamlı, E; Kurt, E; Ulus, T; Verdiyev, H | 1 |
| Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK | 1 |
| Asano, T; Garg, S; Ishibashi, Y; Kageyama, S; Katagiri, Y; Kawashima, H; Kogame, N; Kotoku, N; Kozuma, K; Masuda, S; Miyazaki, Y; Morino, Y; Muramatsu, T; Nakamura, M; Nakatani, S; Nakazawa, G; Ninomiya, K; Okamura, T; Onuma, Y; Ozaki, Y; Serruys, PW; Takahashi, H; Takahashi, K; Tanabe, K; Tateishi, H; Tu, S | 1 |
2 review(s) available for aspirin and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
Topics: Aspirin; Cardiotonic Agents; Clopidogrel; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Time Factors | 2013 |
13 trial(s) available for aspirin and everolimus
| Article | Year |
|---|---|
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Materials Testing; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus | 2013 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Treatment Outcome; Tubulin Modulators | 2014 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome | 2015 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Early Termination of Clinical Trials; Europe; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors; Withholding Treatment | 2015 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Pyridines; Risk Factors; Time Factors; Treatment Outcome | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Intention to Treat Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Clopidogrel Monotherapy vs. Aspirin Monotherapy Following Short-Term Dual Antiplatelet Therapy in Patients Receiving Everolimus-Eluting Coronary Stent Implantation.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Everolimus; Female; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Treatment Outcome | 2020 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Immunosuppressive Agents; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; United States | 2021 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Stroke; Ticagrelor; Treatment Outcome | 2023 |
19 other study(ies) available for aspirin and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Oral everolimus inhibits in-stent neointimal growth.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Vessel Prosthesis Implantation; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endothelium, Vascular; Everolimus; Graft Occlusion, Vascular; Iliac Artery; Immunosuppressive Agents; Muscle, Smooth, Vascular; Rabbits; Sirolimus; Stents; Treatment Outcome; Tunica Intima; Vascular Patency | 2002 |
Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
Topics: Aspirin; Cellular Senescence; Cilostazol; Clopidogrel; Down-Regulation; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Humans; Immunosuppressive Agents; Nitric Oxide Synthase Type III; Oxidative Stress; Paclitaxel; Plasminogen Activator Inhibitor 1; Platelet Aggregation Inhibitors; Sirolimus; Sirtuin 1; Sirtuins; Tetrazoles; Ticlopidine; Vasodilator Agents | 2009 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Reduction Behavior; Sirolimus; Ticlopidine; Time Factors | 2010 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Sirolimus; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
When coronary angiography is not enough to detect spontaneous left main coronary artery dissection.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Metoprolol; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Smoking; Ticlopidine; Treatment Outcome | 2012 |
Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Everolimus; Humans; Male; Myocardial Infarction; Patient Compliance; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sirolimus; Treatment Outcome | 2013 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Drug-Eluting Stents; Everolimus; Female; Graft Occlusion, Vascular; Humans; Male; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Reoperation; Saphenous Vein; Ticlopidine | 2015 |
Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Thrombosis; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Everolimus; Female; Humans; Interferometry; Male; Middle Aged; Neointima; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Postoperative Period; Prosthesis Implantation; Sirolimus; Stents; Swine; Swine, Miniature; Ticlopidine; Tomography, Optical Coherence; Vasa Vasorum; Vasculitis | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2016 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Registries; Sirolimus; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2019 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Proportional Hazards Models; Randomized Controlled Trials as Topic; Single-Blind Method; Stroke | 2019 |
What Is the Optimal Dual Antiplatelet Therapy Strategy After Percutaneous Coronary Intervention in the Era of New-Generation Drug-Eluting Stent?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Family Characteristics; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents | 2020 |
Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model.
Topics: Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Factor Xa Inhibitors; Graft Occlusion, Vascular; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Swine; Tomography, Optical Coherence | 2022 |
How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent.
Topics: Aged; Aspirin; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction | 2021 |
Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN).
Topics: Aspirin; Drug-Eluting Stents; East Asian People; Everolimus; Hemorrhage; Humans; Japan; Percutaneous Coronary Intervention; Pilot Projects; Platinum; Polymers; Prasugrel Hydrochloride; Prospective Studies | 2023 |